CA3194700A1 - Potent and selctive compounds as serotonin 1b receptor modulators - Google Patents
Potent and selctive compounds as serotonin 1b receptor modulatorsInfo
- Publication number
- CA3194700A1 CA3194700A1 CA3194700A CA3194700A CA3194700A1 CA 3194700 A1 CA3194700 A1 CA 3194700A1 CA 3194700 A CA3194700 A CA 3194700A CA 3194700 A CA3194700 A CA 3194700A CA 3194700 A1 CA3194700 A1 CA 3194700A1
- Authority
- CA
- Canada
- Prior art keywords
- oxadiazol
- ethoxy
- methy1
- cyano
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382888.4 | 2020-10-08 | ||
| EP20382888 | 2020-10-08 | ||
| PCT/EP2021/077660 WO2022074103A1 (en) | 2020-10-08 | 2021-10-07 | Potent and selctive compounds as serotonin 1b receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3194700A1 true CA3194700A1 (en) | 2022-04-14 |
Family
ID=73030029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3194700A Pending CA3194700A1 (en) | 2020-10-08 | 2021-10-07 | Potent and selctive compounds as serotonin 1b receptor modulators |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12540133B2 (enExample) |
| EP (2) | EP4225753B1 (enExample) |
| JP (1) | JP7687636B2 (enExample) |
| KR (1) | KR20230107566A (enExample) |
| CN (1) | CN116635390B (enExample) |
| AU (1) | AU2021356114A1 (enExample) |
| CA (1) | CA3194700A1 (enExample) |
| CL (1) | CL2023001021A1 (enExample) |
| DK (1) | DK4225753T3 (enExample) |
| ES (1) | ES2985416T3 (enExample) |
| FI (1) | FI4225753T3 (enExample) |
| HR (1) | HRP20241184T1 (enExample) |
| HU (1) | HUE068199T2 (enExample) |
| IL (1) | IL301806B2 (enExample) |
| LT (1) | LT4225753T (enExample) |
| MX (1) | MX2023004116A (enExample) |
| PL (1) | PL4225753T3 (enExample) |
| PT (1) | PT4225753T (enExample) |
| RS (1) | RS65956B1 (enExample) |
| SI (1) | SI4225753T1 (enExample) |
| WO (1) | WO2022074103A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102993831B1 (ko) | 2020-10-08 | 2026-07-23 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 옥스인돌 유도체의 제조 |
| CN117903116A (zh) * | 2021-08-27 | 2024-04-19 | 杭州阿诺生物医药科技有限公司 | 细胞周期蛋白k降解剂 |
| JP2026521568A (ja) | 2023-06-16 | 2026-06-30 | レウコス バイオテク ソシエダッド リミターダ | ５－ｈｔｒ１ｂ調節因子を用いた固形腫瘍の治療 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW240217B (enExample) | 1992-12-30 | 1995-02-11 | Glaxo Group Ltd | |
| US5801170A (en) | 1993-12-07 | 1998-09-01 | Smithkline Beecham Plc | Heterocyclic biphenylylamides useful as 5HT1D antagonists |
| ZA985542B (en) | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
| SK492001A3 (en) | 1998-07-20 | 2001-08-06 | Merck Patent Gmbh | Biphenyl derivatives |
| HUP0302966A2 (hu) | 2000-07-31 | 2003-12-29 | Smithkline Beecham P.L.C. | Karboxamid-vegyületek és alkalmazásuk humán 11CBY receptor antagonistákként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| WO2007057742A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Novel piperazinone derivatives |
| WO2007077457A2 (en) | 2006-01-06 | 2007-07-12 | The Royal Veterinary College | Treatment of equine laminitis with 5-ht1b/ 1d antagonists |
| EP3348266A1 (en) | 2017-01-16 | 2018-07-18 | Leukos Biotech, S.L. | Combination therapy for treating cancer |
-
2021
- 2021-10-07 EP EP21789678.6A patent/EP4225753B1/en active Active
- 2021-10-07 JP JP2023522401A patent/JP7687636B2/ja active Active
- 2021-10-07 WO PCT/EP2021/077660 patent/WO2022074103A1/en not_active Ceased
- 2021-10-07 US US18/248,393 patent/US12540133B2/en active Active
- 2021-10-07 RS RS20240938A patent/RS65956B1/sr unknown
- 2021-10-07 LT LTEPPCT/EP2021/077660T patent/LT4225753T/lt unknown
- 2021-10-07 DK DK21789678.6T patent/DK4225753T3/da active
- 2021-10-07 KR KR1020237015543A patent/KR20230107566A/ko active Pending
- 2021-10-07 CA CA3194700A patent/CA3194700A1/en active Pending
- 2021-10-07 PT PT217896786T patent/PT4225753T/pt unknown
- 2021-10-07 EP EP24191411.8A patent/EP4445901A3/en not_active Withdrawn
- 2021-10-07 ES ES21789678T patent/ES2985416T3/es active Active
- 2021-10-07 FI FIEP21789678.6T patent/FI4225753T3/fi active
- 2021-10-07 SI SI202130183T patent/SI4225753T1/sl unknown
- 2021-10-07 PL PL21789678.6T patent/PL4225753T3/pl unknown
- 2021-10-07 CN CN202180068969.0A patent/CN116635390B/zh active Active
- 2021-10-07 HU HUE21789678A patent/HUE068199T2/hu unknown
- 2021-10-07 IL IL301806A patent/IL301806B2/en unknown
- 2021-10-07 MX MX2023004116A patent/MX2023004116A/es unknown
- 2021-10-07 AU AU2021356114A patent/AU2021356114A1/en active Pending
- 2021-10-07 HR HRP20241184TT patent/HRP20241184T1/hr unknown
-
2023
- 2023-04-06 CL CL2023001021A patent/CL2023001021A1/es unknown
-
2026
- 2026-01-15 US US19/450,120 patent/US20260138974A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260138974A1 (en) | 2026-05-21 |
| US20240166639A1 (en) | 2024-05-23 |
| WO2022074103A1 (en) | 2022-04-14 |
| KR20230107566A (ko) | 2023-07-17 |
| CL2023001021A1 (es) | 2023-11-24 |
| FI4225753T3 (fi) | 2024-08-29 |
| DK4225753T3 (da) | 2024-08-19 |
| CN116635390A (zh) | 2023-08-22 |
| CN116635390B (zh) | 2026-03-27 |
| ES2985416T3 (es) | 2024-11-05 |
| JP7687636B2 (ja) | 2025-06-03 |
| LT4225753T (lt) | 2024-08-26 |
| IL301806B1 (en) | 2026-01-01 |
| US12540133B2 (en) | 2026-02-03 |
| EP4445901A3 (en) | 2024-12-04 |
| PT4225753T (pt) | 2024-08-30 |
| HRP20241184T1 (hr) | 2024-11-22 |
| EP4445901A2 (en) | 2024-10-16 |
| SI4225753T1 (sl) | 2024-10-30 |
| EP4225753A1 (en) | 2023-08-16 |
| IL301806A (en) | 2023-05-01 |
| AU2021356114A9 (en) | 2024-09-12 |
| IL301806B2 (en) | 2026-05-01 |
| PL4225753T3 (pl) | 2024-11-18 |
| EP4225753B1 (en) | 2024-07-31 |
| JP2023547346A (ja) | 2023-11-10 |
| HUE068199T2 (hu) | 2024-12-28 |
| AU2021356114A1 (en) | 2023-05-18 |
| RS65956B1 (sr) | 2024-10-31 |
| MX2023004116A (es) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118221698A (zh) | Kras g12d抑制剂 | |
| ES2431368T3 (es) | Derivado de isoquinolina substituido en posición 8 y su utilización | |
| JP6444800B2 (ja) | キナーゼ活性の阻害剤 | |
| KR101530117B1 (ko) | 야누스 키나제 억제제 화합물 및 방법 | |
| CA3177080A1 (en) | Compounds useful for inhibiting ret kinase | |
| US20260138974A1 (en) | Potent and selective compounds as serotonin 1b receptor modulators | |
| CN115605475B (zh) | 一种免疫抑制剂、其制备方法和应用 | |
| CN110650959B (zh) | 治疗化合物和组合物及其使用方法 | |
| TW201910306A (zh) | Nlrp3發炎體之選擇性抑制劑 | |
| WO2018214867A1 (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| TW200806675A (en) | Heterobicyclic thiophene compounds and methods of use | |
| TW200914023A (en) | Compounds and compositions as kinase inhibitors | |
| KR20110031372A (ko) | 피리디노-피리디논 유도체, 그의 제조, 및 그의 치료적 용도 | |
| WO2018214866A1 (zh) | 一种氮杂芳基衍生物、其制备方法和在药学上的应用 | |
| CN114787145B (zh) | 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物 | |
| KR20240035830A (ko) | 피리디논 mk2 저해제 및 이의 용도 | |
| JP2018532778A (ja) | ピロリジン誘導体 | |
| JP2024516194A (ja) | Ｐｄ１／ｐｄ－ｌ１阻害剤としての化合物及びその方法 | |
| CA3197032A1 (en) | Pyrazole derivatives as ret kinase inhibitors | |
| HK40057478B (en) | Hpk1 inhibitors and methods of using same | |
| TW202312995A (zh) | 氮雜芳基化合物、其製備方法及應用 | |
| HK40019824B (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| HK40011175A (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| HK40011175B (en) | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof | |
| TW201305153A (zh) | 三唑並吡啶和三唑並吡嗪化合物及其組合物和應用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240927 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240927 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240927 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250922 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250922 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250922 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251003 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251003 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251124 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251124 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251125 |